PharmaCyte Biotech, Inc.

NasdaqCM:PMCB Stock Report

Market Cap: US$7.3m

PharmaCyte Biotech Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PMCB?
Owner TypeNumber of SharesOwnership Percentage
Private Companies50,0000.493%
Hedge Funds527,3765.2%
Institutions623,5056.15%
Individual Insiders626,0446.18%
General Public8,307,23582%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 45.4%.

Top Shareholders

Top 25 shareholders own 18.03% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
5.2%
Intracoastal Capital LLC
527,376US$381.8k0%4.23%
3.12%
Joshua Silverman
316,250US$229.0k533%no data
1.87%
Iroquois Capital Management, LLC
189,350US$137.1k0%7.98%
1.31%
Jonathan Schechter
132,500US$95.9k165%no data
1.25%
Geode Capital Management, LLC
126,603US$91.7k0%no data
0.82%
Equitec Group, LLC
82,727US$59.9k0%0.77%
0.82%
Daniel Asher
82,727US$59.9k0%no data
0.79%
Renaissance Technologies LLC
80,000US$57.9k60.6%no data
0.74%
The Vanguard Group, Inc.
74,919US$54.2k-61.5%no data
0.49%
Jns Holdings Group Llc
50,000US$36.2k0%no data
0.41%
Robert Weinstein
41,250US$29.9k0%no data
0.26%
Schonfeld Strategic Advisors LLC
26,200US$19.0k0%no data
0.22%
Michael Abecassis
22,292US$16.1k696%no data
0.2%
Wayne Walker
20,625US$14.9k0%no data
0.19%
Northern Trust Global Investments
19,208US$13.9k0%no data
0.14%
Citadel Advisors LLC
14,531US$10.5k0%no data
0.1%
Carlos Trujillo
10,400US$7.5k0%no data
0.055%
Tower Research Capital Europe Limited
5,551US$4.0k99.3%no data
0.013%
UBS Asset Management AG
1,323US$957.5-94.1%no data
0.011%
Simplex Trading, LLC
1,100US$796.10%no data
0.0079%
Sea Otter Securities Group LLC
800US$578.90%no data
0.0052%
Bank of America Corporation
524US$379.3-0.76%no data
0.003%
Osaic Wealth, Inc.
303US$219.4-0.33%no data
0.0027%
Covestor Ltd
275US$198.80%no data
0.00037%
Park Square Financial Group, LLC
37US$27.10%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/02 18:46
End of Day Share Price 2026/01/02 00:00
Earnings2025/10/31
Annual Earnings2025/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PharmaCyte Biotech, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WhiteH.C. Wainwright & Co.